DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q5xhn5/biliary_cirrhosis) has announced the addition of the "Biliary Cirrhosis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Biliary Cirrhosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AlbireoPharma
- CymaBay Therapeutics, Inc.
- Dr. Falk Pharma GmbH
- Enanta Pharmaceuticals, Inc.
- GlaxoSmithKline Plc
- Intercept Pharmaceuticals, Inc.
- Johnson & Johnson
- MediGene AG
- NGM Biopharmaceuticals, Inc.
- Shire Plc
- Virobay Inc.
Drug Profiles
- A-4250
- budesonide
- FFP-104
- GSK-2330672
- MBX-8025
- NGM-282
- obeticholic acid
- RhuDex
- SHP-625
- Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis
- ustekinumab
- VBY-825
For more information visit http://www.researchandmarkets.com/research/q5xhn5/biliary_cirrhosis
